As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.
- In 2024, Attruby became the second FDA-approved ATTR-CM medication and the first to nearly completely stabilize TTR (≥90%).
- By the end of 2025, 6.6k unique prescriptions had been written.
- Still, the drug’s cost (and time-honored trust in Pfizer’s Vyndamax) made some providers decide to hold off.
That’s where this secondary analysis comes in. The original Phase 3 trial randomized 611 patients with ATTR-CM to Attruby or placebo. Now, researchers are taking a closer look at KCCQ-OS scores.
- After 30 months, individuals in the Attruby group were more likely to be “alive and well” versus placebo (46% vs. 31%).
- The odds of being “alive and better” were 2.1x higher for patients taking Attruby.
- While both groups’ KCCQ-OS scores dropped over time, the Attruby group fared better on average (-12.9 points for Attruby vs -22.6 for placebo).
So what’s in it for Attruby? Well, quite a lot, since clinicians who were waiting for more data on the new(ish) drug have gotten it, and also BridgeBio’s medication has a real impact on patients’ quality of life.
- Since Attruby’s benefits extend patients’ independence, that keeps them out of the hospital and saves money for them and the health systems they rely on.
This data comes after yet another win for stabilizers: Recent results from AstraZeneca/Ionis’s Wainua trial revealed stabilizers may perform better than silencers for ATTR-CM treatment.
- Wainua’s trial failure plus this new data shows that it takes effective, long-term results to be competitive in the ATTR-CM market.
- That sets the standard for emerging competitors like Intellia’s nex-z CRISPR-based therapy, which would need to stabilize better than Attruby’s 90% rate.
The Takeaway
New secondary analysis data backs up Attruby’s ability to improve quality of life and symptom management for patients with ATTR-CM. In the context of new data supporting the efficacy of stabilizers over silencers, Attruby seems on course to stay competitive.
